Nanotechnology Archives

News and Trends 27 Jul 2022

SomaLogic acquires DNA nanotechnology company Palamedrix

Colorado-based AI data-driven proteomics technology company SomaLogic has entered into an agreement to acquire Palamedrix, Inc., which is involved in DNA nanotechnology. Palamedrix provides scientific and engineering expertise and miniaturization technology, which SomaLogic intends to leverage as it develops the next generation of the SomaScan assay. Proteomic tool The SomaScan assay is a multiplexed, sensitive, quantitative, […]

July 27, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Jul 2022

Nanoparticle can kill cancer cells and aid muscle relaxation

A nanoparticle that is both a nanoheater and a nanothermometer at the same time has been developed by researchers at a Japanese university. The university said this is a significant development that not only aids muscle relaxation, but it can also kill cancer cells. Satoshi Arai and colleagues at Kanazawa University have successfully showed that […]

July 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 30 Jul 2020

Llama-Derived Nanobodies Join the Fight Against Covid-19

Newly-launched Belgian startup ExeVir Bio will develop ‘nanobodies’ that bind very precisely to key areas of the Covid-19 virus and other coronaviruses after raking in €23M in Series A. Based in Ghent, Belgium, ExeVir Bio is a spin-out of the research institute VIB established with the help of life sciences investor Fund+. Other investors include […]

July 30, 2020 - 3 minutesmins - By Victor Kotsev

agrosavfe belgium strawberry pesticide fungal

News and Trends 30 Jul 2019

Belgian Biotech Raises €35M to Develop Eco-Friendly Pesticides

The Belgium-based company AgroSavfe has raised a Series C round of €35M to develop an environmentally friendly crop pesticide inspired by llama antibodies. AgroSavfe will use the funds to develop and manufacture its lead protein fungicide on a commercial scale. The company aims to get approval from the US Environmental Protection Agency and launch the […]

July 30, 2019 - 2 minutesmins - By Jonathan Smith

nanobiotix nanotechnology nanoparticle cancer

More News! 28 May 2019

Nanomedicine Company Launches in France to Improve Drug Safety

The French nanomedicine biotech Nanobiotix is spinning out a subsidiary company developing nanoparticles that can enhance a drug’s effectiveness and decrease side effects. Called Curadigm, the spinout will be developing nanotechnology with the potential to make low drug doses more effective at treating different conditions, which could make treatments cheaper and with fewer side effects […]

May 28, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 22 Jun 2018

Radiotherapy-Enhancing Cancer Nanomedicine Secures Good Phase II/III Results

A nanomedicine designed to help amplify and focus radiation treatment on hard to treat soft tissue sarcoma cells has achieved positive Phase II/III trial results for French-American biotech Nanobiotix. “Data are exceptional and show without any doubt an improvement of radiation therapy impact,” commented Sylvie Bonvalot, Head of Sarcoma and Complex Tumor Surgery Unit at […]

June 22, 2018 - 2 minutesmins - By Helen Albert

Grapevine Fungus Nanoparticle Technology

More News! 31 May 2018

A Trojan Horse of Nanoparticles Could Fight Fungal Infections in Grapevines

German researchers have developed nanoparticles that can protect grapevines from a fungal disease that causes great financial damage to winegrowers each year. A research team at the University of Mainz, led by Frederik Wurm, has developed a nanotechnology that can protect and heal grapevines from infestation by the fungal disease Esca. The technology is made of […]

May 31, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 29 Jan 2018

Another One Gets Snapped Up: Ablynx has been Acquired by Sanofi for €3.9B

Sanofi will acquire Ablynx and get its hands on the biotech’s exciting Nanobody technology just months after the biotech joined Europe’s billion-euro biotech club. Despite rejecting the advances of Novo Nordisk earlier this month, a decision that led to a 60% jump in Ablynx’s stock, the biotech has voted unanimously in favor of being acquired Sanofi. Sanofi has […]

January 29, 2018 - 3 minutesmins - By Alex Dale

Interview 11 Dec 2017

Edwin Moses on how Ablynx has made it to the top of European biotech

Ablynx CEO Edwin Moses discusses the technology and strategy that has led its company to join the ranks of the biggest European biotechs. Ablynx, based in Belgium, has just recently joined the European billion-euro biotech club with a market cap of €1.45Bn. With positive Phase III results for its lead compound and a $230M (€195M) […]

December 11, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Oct 2017

Ablynx Launches $175M IPO on Wall Street After Phase III Success

Fresh from announcing positive Phase III results, Ablynx has wasted no time in filing a $175M (€148M) IPO to continue developing its nanobodies technology. On Monday, the Belgian biotech shared the news that its nanobody, caplacizumab, received encouraging results for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a life-threatening blood disorder. This news boosted the company’s […]

October 4, 2017 - 2 minutesmins - By Alex Dale

sobi hemophilia clotting factor alprolix

News and Trends 2 Oct 2017

Belgian Biotech Breaks New Ground in Fight Against Life-Threatening Blood Disorder

Ablynx has triumphed where others have fallen by receiving positive Phase III results for the treatment of a dangerous blood disorder with caplacizumab. Ablynx develops nanobodies, molecules with the specificity of antibodies but much smaller in size. Its product, caplacizumab, has received encouraging results for the treatment of the life-threatening autoimmune blood disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which […]

October 2, 2017 - 3 minutesmins - By Alex Dale

argenx staten biotechnology dyslipidemia

More News! 23 Aug 2017

Dutch Biotech could treat Dyslipidemia with Belgian Nanobody

Argenx’ partner Staten Biotechnology has published results that present a drug licensed from the Belgian biotech as a promising approach to control blood lipid levels. Staten Biotechnology is a young biotech in Breda, the Netherlands, focusing on treating dyslipidemia and reduce cardiovascular mortality and backed by BioGeneration Ventures and Forbion Capital Partners as investors. Back […]

August 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us